Literature DB >> 3976921

NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel.

.   

Abstract

This report represents the consensus of a panel of representatives from psychiatry, psychology, pharmacology, epidemiology, internal medicine, and the general public regarding the use of pharmacologic agents to prevent recurrences of mood disorders. The panel concluded that recurrent mood disorders, which have a high prevalence and serious consequences, are underdiagnosed and undertreated. Applying appropriate strategies to the management and use of pharmacologic agents will enhance the likelihood of compliance and the prevention of recurrence with a minimum of bothersome side effects. Such strategies should be used within the context of a supportive relationship among doctor, patient, and family.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3976921     DOI: 10.1176/ajp.142.4.469

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  20 in total

Review 1.  Therapeutic drug monitoring of psychotropic medications.

Authors:  P B Mitchell
Journal:  Br J Clin Pharmacol       Date:  2000-04       Impact factor: 4.335

Review 2.  Lithium: serum levels, renal effects, and dosing strategies.

Authors:  M J Gitlin
Journal:  Community Ment Health J       Date:  1992-08

3.  Counseling via analogy: improving patient adherence in major depressive disorder.

Authors:  Boadie W Dunlop; Anne L Dunlop
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 4.  Risks and benefits of selective serotonin reuptake inhibitors in the treatment of depression.

Authors:  P Mourilhe; P E Stokes
Journal:  Drug Saf       Date:  1998-01       Impact factor: 5.606

5.  Lithium for acute mania.

Authors:  Rebecca F McKnight; Saïk J G N de La Motte de Broöns de Vauvert; Edward Chesney; Ben H Amit; John Geddes; Andrea Cipriani
Journal:  Cochrane Database Syst Rev       Date:  2019-06-01

6.  Cost utility of maintenance treatment of recurrent depression with sertraline versus episodic treatment with dothiepin.

Authors:  E J Hatziandreu; R E Brown; D A Revicki; R Turner; J Martindale; S Levine; J E Siegel
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

Review 7.  Selective serotonin reuptake inhibitors. Assessment for formulary inclusion.

Authors:  B H Guze
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

8.  Modelling the cost effectiveness of antidepressant treatment in primary care.

Authors:  D A Revicki; R E Brown; W Palmer; D Bakish; W W Rosser; S F Anton; D Feeny
Journal:  Pharmacoeconomics       Date:  1995-12       Impact factor: 4.981

9.  A Markov process analysis comparing the cost effectiveness of maintenance therapy with citalopram versus standard therapy in major depression.

Authors:  M J Nuijten; M Hardens; E Souêtre
Journal:  Pharmacoeconomics       Date:  1995-08       Impact factor: 4.981

10.  Cost analysis of paroxetine versus imipramine in major depression.

Authors:  J D Bentkover; J P Feighner
Journal:  Pharmacoeconomics       Date:  1995-09       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.